APOC TBI webinars

WEBINARS

CHALLENGES IN MILD TRAUMATIC BRAIN INJURY (MTBI) ASSESSMENT AND THE NEXT FRONTIER IN BIOMARKER TESTING

Live event: November 11, 2021

An estimated 69 million patients¹ worldwide sustain a traumatic brain injury (TBI) each year of which more than 80% are classified as mild (GCS 13 to 15)². Due to the limitations of current evaluation tools, mTBI assessment can be time- and resource-consuming.

Join leading experts in an upcoming webinar to learn about the latest research into blood plasma-based biomarkers and their potential to predict the absence of intracranial injury. During this webinar, you’ll hear how two proteins, Ubiquitin C-terminal hydrolase-L1 (UCH-L1) and Glial fibrillary acidic protein (GFAP), have emerged as promising biomarkers that can be used in conjunction with other clinical information to aid in the evaluation of suspected mTBI patients in the ED.

¹Dewan MC et al. J Neurosurg. 2004;43(suppl):113-125.
²Korley FK et al. J Head Trauma Rehabil. 2016;31(6):379-387.

Learning Objectives:

• Examine challenges and shortcomings of the current approaches to mTBI evaluation in the ED
• Review the latest advancements in TBI biomarkers, including identifying brain-specific biomarkers with characteristics that offer diagnostic value in the ED
• Describe how blood plasma-based biomarker testing can be used in conjunction with other clinical information to aid in the evaluation of suspected mTBI patients and reduce diagnostic uncertainty by providing the quantitative measurement of biomarkers producing an objective interpretation.
• Examine the potential for biomarker testing to reduce unnecessary head CT, improve patient care and satisfaction, and improve operational efficiency

PROFESSOR PETER BIBERTHALER, MD

Professor Peter Biberthaler’s research activities concentrate on his core clinical focus areas. A very important aspect of these focus areas is the care of severe and multiple trauma patients, a major part of which is the treatment of traumatic brain injuries.

Professor Biberthaler’s other major focus area, shoulder surgery, is the logical consequence of his scientific research and clinical practice in the field of traumatology. He is the first person to have been able to visualize the blood circulation in direct proximity to ruptures by means of intraoperative intravital-microscopic imaging.

PAUL JARVIS, MD, BSC(HONS) MBCHB MRCP FRCEM DIP MED ED MSC

Dr. Jarvis is the Director of Global Medical Affairs at Abbott Point of Care. In addition, he is a practicing Emergency Medicine Physician working in the North of England. He has over 20 years of clinical experience with particular interests in Neurological Emergencies and Trauma management. He has a Masters Degree in Quality Improvement from Ashridge Business School, United Kingdom. Parallel to his clinical work, Paul ran a global management consultancy for 5 years, helping hospitals around the world improve their patient flow.

Recording

Slides

Learn More

One P.A.C.E.^® contact hour will be provided for this basic level session for six months following the live event. Abbott is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.^® Program. This session is approved for one Florida CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563

USING BIOMARKERS FOR OBJECTIVE ASSESSMENT OF MILD TRAUMATIC BRAIN INJURY

Live event: July 22, 2021

Traumatic brain injury (TBI) is evaluated during ~5 million ED visits annually¹ of which more than 80% are classified as mild (GCS 13 to 15)². Due to the limitations of current evaluation tools, mTBI assessment can be time- and resource-consuming.

Join leading experts in an upcoming webinar to learn about the latest research into blood-based biomarkers and their potential to predict the absence of intracranial injury. During this webinar, you’ll hear how two proteins, Ubiquitin C-terminal hydrolase-L1 (UCH-L1) and Glial fibrillary acidic protein (GFAP), have emerged as promising biomarkers that can be used in conjunction with other clinical information to aid in the evaluation of suspected mTBI patients in the ED.

¹Korley FK et al. J Head Trauma Rehabil. 2016;31(6):379-387.
²Dewan MC et al. J Neurosurg. 2004;43(suppl):113-125.

Learning Objectives:
• Examine challenges and shortcomings of the current approaches to mTBI evaluation in the ED

• Review the latest advancements in TBI biomarkers, including identifying brain-specific biomarkers with characteristics that offer diagnostic value in the ED

• Describe how blood-based biomarker testing can be used in conjunction with other clinical information to aid in the evaluation of suspected mTBI patients and reduce diagnostic uncertainty by providing a quantifiable objective assessment

• Examine the potential for biomarker testing to reduce unnecessary head CT, improve patient care and satisfaction, and improve operational efficiency

JESSE M. PINES, MD, MBA, MSCE

Jesse Pines MD, is the National Director of Clinical Innovation at US Acute Care Solutions and a Professor of Emergency Medicine at Drexel University. Dr. Pines leads USACS’s efforts in telemedicine, alternative payment models, and opioids. Dr. Pines is a nationally known expert in ED quality of care, innovation, and health services research, and has published more than 330 peer-reviewed publications and six books. Before joining USACS in 2018, he served as the Director of the Center for Healthcare Innovation and Policy Research and Professor at George Washington University and Professor, and also previously was Assistant Professor at the University of Pennsylvania.

PAUL JARVIS, MD, BSC(HONS) MBCHB MRCP FRCEM DIP MED ED MSC

Dr. Paul Jarvis is the Director of Global Medical Affairs at Abbott Point of Care. In addition, he is a practicing Emergency Medicine Physician working in the North of England. He has over 20 years of clinical experience with particular interests in Neurological Emergencies and Trauma management. He has a Masters Degree in Quality Improvement from Ashridge Business School, United Kingdom. Parallel to his clinical work, Paul ran a global management consultancy for 5 years, helping hospitals around the world improve their patient flow.

JEFFREY BAZARIAN, MD

Dr. Jeffrey Bazarian is a Professor of Emergency Medicine and Neurology with an active, interdisciplinary, clinical research program in mild TBI and sport concussions at the University of Rochester. He has served as the lead investigator on projects to determine the epidemiology and outcome of mild TBI (K23 from NINDS), to image with DTI axonal injury acutely after mild TBI (R01 from NICHD), to determine the role of serum S100B in the diagnosis of intracranial hemorrhage after mild TBI (New York State Department of Health), to validate new putative markers of axonal injury (K24 NICHD), and to investigate the nature of white matter damage after multiple sub-concussive head blows (NFL-Charities). His lab’s translational research platform involving contact athletes at the University of Rochester and Rochester Institute of Technology incorporates DTI, fMRI, and cognitive/balance performance with head accelerometer data, as well as with serum and whole blood sampling for protein and genetic analysis, respectively.

Recording

Slides

Learn More

TRAUMATIC BRAIN INJURY BEST PRACTICES AND OPPORTUNITIES: FROM ACUTE EVALUATION TO POST-DISCHARGE

Live event: December 7, 2020

Worldwide each year, 50 million+ people sustain a traumatic brain injury (TBI). Symptoms resolve quickly for many patients, while others can take several weeks to months for post-concussive symptoms to resolve, and yet another subset of patients continue to experience persistent symptoms for 3 months or more after injury. However, due to the limitations of currently used evaluation tools, TBI can be challenging to adequately screen, manage and develop therapeutic treatments to improve outcomes.

Hear from leading experts about effective strategies and trends related to head injury evaluation and an update regarding potential advances in biomarker research. Biomarkers have the potential to aid in the evaluation of TBI and have demonstrated the ability to predict the absence of intracranial injury. Two proteins, Ubiquitin C-terminal hydrolase-L1 (UCH-L1) and Glial fibrillary acidic protein (GFAP), have emerged as promising biomarkers for clinical use to predict traumatic intracranial injuries on head CT scan acutely after TBI.

Learning Objectives:
• Describe unmet needs and challenges regarding the current tools and approach to traumatic brain injury evaluation
• Examine how the current approach to TBI evaluation impacts patient care and burden to the hospital
• Discuss the long-term impact of mild TBI and what Emergency Departments can do to improve outcomes
• Identify developments regarding the use of biomarkers for TBI evaluation and discuss the ways in which biomarkers may be used in the future clinically to improve patient care

ALASTAIR M. JONES, MBCHB, FRCEM, PGDIP

Dr Alastair Jones is a Consultant in Emergency Medicine at the Bradford Teaching Hospitals Foundation Trust. Alastair qualified in Medicine from the University of Sheffield in 2003. He obtained Fellowship to the Royal College of Emergency Medicine in 2011 and Membership to the Faculty of Sports and Exercise Medicine in 2019. He also achieved a Post-Graduate Diploma in Sports and Exercise Medicine from the University of Bath in 2016. His areas of clinical interest include Musculoskeletal Medicine, Sports and Exercise Medicine, and Sports Concussion. Alastair developed and leads the Bradford Royal Infirmary Acute Musculoskeletal Clinic, a multidisciplinary clinic for patients with musculoskeletal injuries.

Dr. Jones is also heavily involved in Sports and Exercise Medicine and held the post of Head of Medical Services for Leeds Rugby where he oversaw the medical departments of both Leeds Rhinos Rugby League and Yorkshire Carnegie Rugby Union. He currently provides medical services for the Rugby Football Union as the course director for the Rugby Football Unions Pre-Hospital Immediate Care in Sport Course and forms part of the Twickenham Stadium international match day medical team. He also works as a match day doctor for Premiership Rugby. Dr. Jones previously worked for Tonga during the 2013 Rugby League World Cup and held the role of Immediate Care Doctor at the 2015 Rugby Union World Cup and 2016 Rugby Union Junior World Cup.

THOMAS K. WATANABE, MD

Thomas Watanabe, MD is Clinical Director of the Drucker Brain Injury Center at MossRehab, director of the MossRehab Stroke program and Associate Professor in the Department of Physical Medicine and Rehabilitation at the Temple University School of Medicine in Philadelphia. He oversees the clinical aspects of the inpatient and outpatient brain injury and stroke programs as well as participating in the strategic planning for programs at MossRehab in general. He is also actively involved in the training of residents and medical students in the medical care and rehabilitation of persons with neurological diagnoses.

Dr. Watanabe is a co-investigator on the current Traumatic Brain Injury Model System grant supported by the NIDILRR and has participated in several other clinical trials related to recovery after stroke and brain injury. He has authored or co-authored several peer-reviewed articles directly related to the treatment of individuals with acquired brain injuries as well as other invited articles and book chapters. Dr. Watanabe is on the editorial board of The Journal of Head Trauma Rehabilitation. He has also given many local, regional, national and international presentations to health care professionals on various aspects of neurorehabilitative care.

Recording

Slides

Back to
TBI Resources

ADVANCES IN TRAUMATIC BRAIN INJURY EVALUATION AND MANAGEMENT

Live event: July 23, 2020

Worldwide each year, 50 million+ people sustain a traumatic brain injury (TBI); most cases are mild with variable clinical outcomes and lasting symptoms¹. Hear from leading experts about effective strategies and trends related to head injury evaluation. The latest blood-based biomarker research and their potential to predict the absence of intracranial injury will also be presented.

This webinar will discuss how biomarkers may be used in the future clinically to improve patient care in the hospital and outpatient care setting. It will also identify the role of brain biomarker tests in the hospital performance.

Learning Objectives:
• Describe unmet needs and challenges regarding the current tools and approach to traumatic brain injury evaluation
• Examine how the current approach to TBI evaluation impacts patient care and burden to the hospital
• Identify developments regarding the use of biomarkers for TBI evaluation
• Discuss the ways in which biomarkers may be used in the future clinically to improve patient care in the hospital and outpatient care setting
• Assess the role of brain biomarker tests in the hospital performance

^{1 Nelson LD et al. Recovery
after mild traumatic brain injury in patients presenting to
US level I trauma centers. JAMA Neurol.2019;76(9):1049.}

JEFFREY J. BAZARIAN, MD, MPH

Dr. Bazarian is Professor of Emergency Medicine and Neurology at the University of Rochester. He is a graduate of Brown University and the University of Rochester School of Medicine and Dentistry. He is board certified in Internal Medicine and Emergency Medicine but practiced Emergency Medicine exclusively for 22 years until 2012. In 2010, Dr. Bazarian joined the University of Rochester Sports Concussion Clinic, providing outpatient concussion care to area high school and collegiate athletes.

Dr Bazarian’s research is focused on developing neuroimaging and blood-based biomarkers of axonal injury after concussion and repetitive head hits, and the pathophysiologic mechanisms of recovery. He, along with Dr Welch, were lead authors on the 2018 Lancet Neurology publication detailing the results of the multi-national ALERT-TBI trial used to support FDA clearance of the first test to use blood-based biomarkers of traumatic brain injury in the US.

ROBERT D. WELCH, MD, MS, FACEP,

Dr. Welch is Professor, Clinical Educator, in the Department of Emergency Medicine and is the Director of the Biostatistics and Epidemiology Research Design Group. He is a member of the Cardiovascular Research Institute and an Associate in the Department of Physical Medicine and Rehabilitation at Wayne State University School of Medicine in Detroit, Michigan.

Dr. Welch completed his MD degree at Wayne State University School of Medicine, his residency in Emergency Medicine at Detroit Receiving Hospital / Wayne State University, and a M.S. in Clinical Research Design and Statistical Analysis at the University of Michigan. Rob’s interests include neurological emergencies, clinical trials methodology and heart disease. He was the Program Director of the Wayne State University Neurological Emergencies Treatment Trials Network from 2007 – 2018 and held numerous clinical research contracts with foundations and industry.

Recording

Slides

Back to
TBI Resources